These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 31676281

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.
    Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
    [Abstract] [Full Text] [Related]

  • 23. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
    Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, Lu C, Rescigno P, Kolinsky M, Bertan C, Seed G, Riisnaes R, Miranda S, Crespo M, Pereira R, Ferreira A, Fowler G, Ebbs B, Flohr P, Neeb A, Bianchini D, Petremolo A, Sumanasuriya S, Paschalis A, Mateo J, Tunariu N, Yuan W, Carreira S, Plymate SR, Luo J, de Bono JS.
    Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
    [Abstract] [Full Text] [Related]

  • 24. Assessment of Total, PTEN-, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide.
    Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, Scafuri L, Verde A, Bruzzese D, Iaccarino S, Costabile F, Onofrio L, Viggiani M, Palmieri A, De Placido P, Marretta AL, Pietroluongo E, Luce A, Abate M, Navaeiseddighi Z, Caputo VF, Celentano G, Longo N, Ferro M, Morelli F, Facchini G, Caraglia M, De Placido S, Buonerba C.
    Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
    Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.
    Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394
    [Abstract] [Full Text] [Related]

  • 26. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
    Halabi S, Guo S, Park JJ, Nanus DM, George DJ, Antonarakis ES, Danila DC, Szmulewitz RZ, McDonnell DP, Norris JD, Lu C, Luo J, Armstrong AJ.
    Clin Cancer Res; 2024 Mar 15; 30(6):1152-1159. PubMed ID: 38236581
    [Abstract] [Full Text] [Related]

  • 27. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J.
    Eur Urol; 2017 Jan 15; 71(1):1-3. PubMed ID: 27471164
    [Abstract] [Full Text] [Related]

  • 28. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Shenderov E, Boudadi K, Fu W, Wang H, Sullivan R, Jordan A, Dowling D, Harb R, Schonhoft J, Jendrisak A, Carducci MA, Eisenberger MA, Eshleman JR, Luo J, Drake CG, Pardoll DM, Antonarakis ES.
    Prostate; 2021 May 15; 81(6):326-338. PubMed ID: 33636027
    [Abstract] [Full Text] [Related]

  • 29. Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.
    Sciarra A, Gentilucci A, Silvestri I, Salciccia S, Cattarino S, Scarpa S, Gatto A, Frantellizzi V, Von Heland M, Ricciuti GP, Del Giudice F, Maggi M.
    Medicine (Baltimore); 2019 May 15; 98(19):e15608. PubMed ID: 31083254
    [Abstract] [Full Text] [Related]

  • 30. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
    Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González Del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D, PREMIERE Collaborators, Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G.
    Ann Oncol; 2017 Jul 01; 28(7):1508-1516. PubMed ID: 28472366
    [Abstract] [Full Text] [Related]

  • 31. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
    Liu C, Armstrong C, Zhu Y, Lou W, Gao AC.
    Oncotarget; 2016 May 31; 7(22):32210-20. PubMed ID: 27049719
    [Abstract] [Full Text] [Related]

  • 32. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
    Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW.
    Clin Cancer Res; 2017 Feb 01; 23(3):726-734. PubMed ID: 27489290
    [Abstract] [Full Text] [Related]

  • 33. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.
    Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Berry WR, Zhang T, Harrison MR, Lu C, Chen Y, Galletti G, Schonhoft JD, Scher HI, Wenstrup R, Tagawa ST, Antonarakis ES, George DJ, Halabi S.
    JCO Precis Oncol; 2020 Feb 01; 4():. PubMed ID: 33154984
    [Abstract] [Full Text] [Related]

  • 34. The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
    Liu RJ, Hu Q, Li SY, Mao WP, Xu B, Chen M.
    Technol Cancer Res Treat; 2021 Feb 01; 20():15330338211035260. PubMed ID: 34313171
    [Abstract] [Full Text] [Related]

  • 35. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
    Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES.
    Ann Oncol; 2015 Sep 01; 26(9):1859-1865. PubMed ID: 26117829
    [Abstract] [Full Text] [Related]

  • 36. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
    Gupta S, Halabi S, Kemeny G, Anand M, Giannakakou P, Nanus DM, George DJ, Gregory SG, Armstrong AJ.
    Mol Cancer Res; 2021 Jun 01; 19(6):1040-1050. PubMed ID: 33771885
    [Abstract] [Full Text] [Related]

  • 37. Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Maillet D, Allioli N, Péron J, Plesa A, Decaussin-Petrucci M, Tartas S, Sajous C, Ruffion A, Crouzet S, Freyer G, Vlaeminck-Guillem V.
    Cancers (Basel); 2021 Nov 29; 13(23):. PubMed ID: 34885125
    [Abstract] [Full Text] [Related]

  • 38. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
    Wang J, Zhang Y, Wei C, Gao X, Yuan P, Gan J, Li R, Liu Z, Wang T, Wang S, Liu J, Liu X.
    Front Oncol; 2020 Nov 29; 10():562504. PubMed ID: 33330031
    [Abstract] [Full Text] [Related]

  • 39. [AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].
    Büchler T, Bobek V, Kološtová K.
    Klin Onkol; 2017 Nov 29; 31(1):9-14. PubMed ID: 29488772
    [Abstract] [Full Text] [Related]

  • 40. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug 29; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.